Latest news with #AinnovaTech
Globe and Mail
3 days ago
- Business
- Globe and Mail
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS , June 4, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas , Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: - technologies - ai Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Globe and Mail
16-05-2025
- Business
- Globe and Mail
Early Movers in Health AI Are Starting to Separate from the Pack
Issued on behalf of Avant Technologies Inc. VANCOUVER – News Commentary – AI is rewriting the rules of healthcare —not in a burst, but in a careful, calculated march that balances innovation with caution. That same tension is playing out in statehouses like Connecticut's, where lawmakers are weighing how to regulate AI while also addressing the urgent needs of a strained healthcare workforce. Meanwhile, OpenAI just took its biggest step yet into health tech by releasing HealthBench, a benchmark dataset designed to test how well large language models can answer medical questions. Amid this flurry of policy, infrastructure, and research activity, several public companies are emerging as early leaders at the intersection of generative AI and healthcare—among them Avant Technologies, Inc. (OTCQB: AVAI), Inc. (NASDAQ: AMZN), Royal Philips (NYSE: PHG), NVIDIA Corporation (NASDAQ: NVDA), and Oracle Corporation (NYSE: ORCL). Analysts at MarketsandMarkets are forecasting the AI in Healthcare Market to surge at a massive 38.6% CAGR to an impressive US$110.61 billion by 2030. By 2035, Accenture analysts believe AI could add another $461 billion in value to a healthcare industry already on track to surpass $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI) is quietly but deliberately advancing its position in AI-powered healthcare through a proposed acquisition of its joint venture partner, Ainnova Tech. The two companies, already aligned under the Ai-nova Acquisition Corp. (AAC) banner, are now moving to unify operations—an intentional step that comes just ahead of their scheduled FDA pre-submission meeting this July. If completed, the merger would remove internal friction, streamline clinical trial planning, and strengthen their regulatory posture ahead of potential U.S. market entry. 'We believe bringing the two companies together will offer tremendous value for shareholders,' said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. 'It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.' At the core of this effort is Vision AI, a non-invasive clinical screening platform that combines retinal imaging, vital sign capture, and machine-learning algorithms to detect early signals of chronic illness—including diabetic retinopathy, cardiovascular disease, kidney and liver conditions, and type 2 diabetes. Operating under AAC, the joint venture holds global rights to the platform, which has shown more than 90% sensitivity in early detection, according to NIH -cited research. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,' said Vargas. 'Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." Unlike many healthcare AI startups still stuck at concept stage, Avant's technology is already deployed in Latin America —including Chile, Mexico, and Brazil —where it's being tested in real-world clinical workflows. These field programs are not only helping build a safety and efficacy track record, they're also providing critical user feedback that shapes the platform's refinement and usability. To support broader clinical reach, AAC recently integrated four new diagnostic algorithms into Vision AI. Trained on over 2.3 million clinical cases, these additions enhance the system's utility across a wider range of chronic conditions. With proven traction abroad and a pending regulatory milestone in the U.S., Avant is moving from potential to presence—and may soon find itself on the radar of a much larger healthcare conversation. Inc. (NASDAQ: AMZN) through AWS, is advancing real-world health applications of generative AI with tools like Health Kaki —a personalized AI companion developed for Singapore's Ministry of Health. Powered by AWS Bedrock and Anthropic's Claude 3.5 Sonnet, Health Kaki delivers diet and exercise recommendations that align with cultural norms, clinical guidelines, and user preferences. Its success in moving from concept to production highlights AWS's role in building scalable, user-centric healthcare AI. With robust guardrails and modular architecture, AWS is positioning itself as a key infrastructure provider in the global shift toward 'well care.' Royal Philips (NYSE: PHG) has partnered with NVIDIA Corporation (NASDAQ: NVDA) to co-develop a foundational AI model aimed at revolutionizing magnetic resonance (MR) imaging. 'Our AI-powered MRI solutions are already enabling healthcare providers to deliver better care to more people,' said Dr. Ioannis Panagiotelis, Business Leader of MRI at Philips. 'By partnering with NVIDIA to build an MR Foundational Model, we're pioneering a new frontier for medical imaging, one that has the potential to transform the role of MR in the diagnosis and treatment of a wide range of diseases. The benefits for patients and healthcare providers could be enormous.' The initiative, announced at ISMRM 2025, will leverage NVIDIA's VISTA-3D and MAISI platforms to create a next-generation diagnostic tool that improves image quality, reduces scan times, and streamlines workflow. The AI-powered model will support features like zero-click scan planning, denoising, and real-time image preview, enhancing speed and accuracy for radiologists. This collaboration positions both companies at the forefront of AI-driven precision imaging, with broad implications for diagnostics and patient care. Oracle Corporation (NYSE: ORCL) has expanded access to its Oracle Health Clinical AI Agent in Canada, bringing its generative AI-powered documentation assistant to a growing list of medical specialties. "Time is our most precious, non-renewable resource," said Erin O'Halloran, vice president and Canada market leader, Oracle Health. ' Oracle Health Clinical AI Agent helps to restore the clinician-patient relationship, emphasize focused time with patients, and reduce clinician burnout. The availability of this solution marks another step toward modernizing the country's health information systems and providing a more digitally connected healthcare ecosystem." The platform has already helped U.S. healthcare providers cut documentation time by 30%, freeing up clinicians to focus more on patient care. Integrated directly into Oracle's electronic health records system, the AI agent drafts notes, navigates patient histories, and suggests next steps in real time. Source: CONTACT: cs@ (250) 661-3391 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Media Corp. ('BAY') BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Associated Press
06-05-2025
- Business
- Associated Press
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company's Vision AI Platform Technology
LAS VEGAS, May 6, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company'), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy. Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, 'We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S.' 'We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable.' AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product. About Ainnova Tech, Inc. Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute 'forward-looking statements.' Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release. Contact: Avant Technologies, Inc. [email protected] Video: Logo: View original content to download multimedia: SOURCE Avant Technologies Inc.
Yahoo
10-03-2025
- Business
- Yahoo
Apollo Hospitals partners with Ainnova Tech for AI-driven disease detection
Apollo Hospitals has announced a strategic collaboration with Ainnova Tech, a healthcare technology company, to integrate artificial intelligence (AI) into disease detection and prediction. This partnership has led to Ainnova securing an exclusive license for advanced AI algorithms, validated with more than 2.3 million data points, for its Vision AI platform. These AI solutions are designed to enhance the early and precise detection of various conditions, including liver fibrosis, cardiovascular and chronic kidney diseases, type 2 diabetes, and lung abnormalities. Last month, Avant Technologies and Ainnova formed a joint venture, Ai-Nova Acquisition (AAC), and signed a global development and licensing deal. With AAC now holding a global licence to develop and market Ainnova's technology, the collaboration with Apollo strengthens the venture's global efforts to advance AI in healthcare. These AI-driven diagnostics are set to be available on the Vision AI platform across the Americas, with the first commercial pilot programmes launching soon. With a population of over 200 million, Brazil is set to expand, having met the regulatory requirements of Brazil's Health Regulatory Agency, ANVISA. Integrating the AI-powered solution aims to enhance chronic disease management by adding value to patient care. These tools offer a comprehensive preventive health assessment and will enable early referrals from primary care or community health services to specialised medical professionals. Apollo and Ainnova aim to further develop and deploy AI-driven healthcare solutions, with additional innovations expected to be introduced shortly. Earlier this month, Apollo Hospitals signed a term sheet with Ion Beam Applications (IBA) for the procurement of one ProteusONE compact proton therapy solution. "Apollo Hospitals partners with Ainnova Tech for AI-driven disease detection" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
